The amdinocillin market is gaining attention as healthcare systems seek targeted antibiotic therapies for bacterial infections, particularly urinary tract infections. The drug, also known as mecillinam, belongs to the amdinopenicillin class and has activity against Gram-negative bacteria. The Amdinocillin Market is projected to grow from US$ 1.28 billion in 2025 to US$ 2.78 billion by 2034,...